Regeneron Pharmaceuticals, Inc. (REGN) stock
Close on Nov 11, 2026Market cap $99.25BP/E 21.2Yield –
Regeneron Pharmaceuticals, Inc. grew revenue 18.6% to $16.90B over the twelve months to Sep 30, 2026. Operating income rose 31.9% to $4.86B, moving the operating margin from 25.9% to 28.8%. Free cash flow was $3.83B, down 9.4% from a year earlier. At the latest close the market valued the company at $99.25B, 21.2 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $99.25B
- P/E ratio
- 21.2
- Price to sales
- 5.87
- Price to book
- 2.96
- Dividend yield
- –
- Free cash flow yield
- 3.86%
Fundamentals
- Revenue
- $16.90B
- Net income
- $4.82B
- EPS, diluted
- $45.27
- Free cash flow
- $3.83B
- Book value per share
- $317.22
- Diluted shares
- 106M
Trading
- Next earnings
- Jan 29, 2027 (estimated, before the open)
- Previous close
- $916.06
- Open
- $904.99
- Day's range
- $898.29 – $961.98
- Volume
- 1,233,521
- Average volume (20 days)
- 963,399
- Index membership
- S&P 500, Nasdaq-100, Russell 1000, Russell 3000
- Beta (5 years)
- 0.62
- 52-week range
- $591.52 – $991.73
- RSI (14 days)
- 70.0
- Volatility (1 year)
- 34.2%
- Relative volume
- 1.58×
- WACC
- 7.9%
On 1 of our idea list: Buyback cannibals
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, QQQ, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | REGN | S&P 500 | Difference | REGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +28.5% | -2.4% | +30.9 pts | ||
| 3 months | +20.5% | -1.2% | +21.7 pts | ||
| Year to date | +24.8% | +12.3% | +12.5 pts | ||
| 1 year | +43.0% | +12.4% | +30.5 pts | ||
| 3 years | +21.2% | +78.8% | −57.6 pts | +6.6% | +21.4% |
| 5 years | +54.5% | +75.2% | −20.6 pts | +9.1% | +11.9% |
| 10 years | +130.7% | +311.1% | −180.4 pts | +8.7% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Regeneron Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Regeneron Pharmaceuticals
Pharmaceutical Preparations
Regeneron Pharmaceuticals, Inc. is a biotechnology enterprise that discovers, invents, develops, manufactures, and commercializes medicines for serious medical conditions. Its commercial portfolio and clinical pipeline address eye diseases, allergic and inflammatory conditions, oncology, cardiovascular and metabolic disorders, neurological conditions, hematologic conditions, infectious diseases, and rare disorders. Key commercial medicines include EYLEA and EYLEA HD for retinal diseases, Dupixent for inflammatory indications, Libtayo for oncology, and Kevzara for inflammatory arthritis. The company serves patients and medical professionals requiring specialized prescription treatments.
Company profile, executives and historyRegeneron Pharmaceuticals stock: common questions
What is Regeneron Pharmaceuticals's stock price?
REGN closed at $959.41 on Nov 11, 2026, up 4.73% on the day. Over the past 52 weeks it traded between $591.52 and $991.73.
What is Regeneron Pharmaceuticals's market cap?
Regeneron Pharmaceuticals was worth $99.25B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is REGN's P/E ratio?
REGN trades at 21.2 times earnings, based on diluted earnings per share of $45.27 over the twelve months to Sep 30, 2026.
How much revenue does Regeneron Pharmaceuticals make?
Regeneron Pharmaceuticals reported revenue of $16.90B for the twelve months to Sep 30, 2026, up 18.6% from a year earlier.
Does Regeneron Pharmaceuticals pay a dividend?
No. Regeneron Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Regeneron Pharmaceuticals report earnings next?
Regeneron Pharmaceuticals is expected to report Q4 FY2026 results on Jan 29, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has REGN stock performed over the past year?
Including dividends, REGN returned +43.0% over the past year, against +12.4% for the S&P 500.
How many REGN shares are sold short?
2M shares were sold short at the latest FINRA report, 2.23% of the float, or 2.7 days of average trading volume.
Who are Regeneron Pharmaceuticals's competitors?
Companies most similar to Regeneron Pharmaceuticals by business, industry and size include VRTX, ALNY, TEVA, JAZZ, GMAB.
See a number that looks wrong?